Switch to:
Also traded in: Australia, Germany, USA

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
» NVGN's 10-Y Financials

Financials (Next Earnings Date: 0)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

NVGN Guru Trades in Q3 2015

Jim Simons 167,800 sh (-22.17%)
» More
Q4 2015

NVGN Guru Trades in Q4 2015

Jim Simons 139,100 sh (-17.10%)
» More
Q1 2016

NVGN Guru Trades in Q1 2016

Jim Simons 137,300 sh (-1.29%)
» More
Q2 2016

NVGN Guru Trades in Q2 2016

Jim Simons 137,300 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with NVGN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:NAS:PRPH, NAS:ALQA, OTCPK:SUWN, OTCPK:INNV, OTCPK:CHEXF, AMEX:AXN, NAS:IMNP, AMEX:CPHI, NAS:BSPM, OTCPK:ECTE, NAS:TNXP, OTCPK:INBP, NAS:ALIM, OTCPK:BIOYF, AMEX:NNVC, NAS:ASMB, NAS:OASM, NAS:NBRV, NAS:ZGNX, NAS:BITI » details
Traded in other countries:NRT.Australia, NV9B.Germany, NVGNF.USA,
Novogen Ltd is a pharmaceutical drug development based on a simple benzopyran chemical structure.

Novogen Ltd. was incorporated in March 1994 under the jurisdiction of the laws of New South Wales, Australia. The Company is engaged in pharmaceutical drug development. It develops single drug capable of killing both the dominant differentiated cells in a cancer as well as the undifferentiated cancer stem cells at a therapeutic dose. The Company's inaugural drug candidate CS-6 belongs to a new class of drug candidates known as Mitochondrial Electron Transfer Inhibitors that work by depriving the cancer cell of its main energy source. The Company's competitors include pharmaceutical companies and biotechnology companies, as well as universities and public and private research institutions. The activities of the Company are subject to numerous Australian laws and regulations.

Ratios

vs
industry
vs
history

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history

More Statistics

Revenue (TTM) (Mil) $0.19
EPS (TTM) $ -0.49
Beta0.95
Short Percentage of Float0.10%
52-Week Range $1.72 - 3.22
Shares Outstanding (Mil)17.16

Analyst Estimate


Warning: Invalid argument supplied for foreach() in /home/gurufocu/public_html/modules/stock/estimate.php on line 163
Jun16 Jun17 Jun18
Revenue (Mil $) 2 4 3
EPS ($) -0.55 -0.56 -0.74
EPS w/o NRI ($) -0.55 -0.56 -0.74
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for NVGN

Headlines

Articles On GuruFocus.com
Novogen (NVGN) Promising Data in Brain Cancer; eFuture Information Technology (EFUT) and NeoPhotonic Mar 04 2015 

More From Other Websites
Novogen Submits IND Application to the US FDA for Cantrixil in Ovarian Cancer Aug 14 2016
Novogen Submits Investigational New Drug (IND) Application to the US FDA For Cantrixil(TM) in... Aug 11 2016
Novogen Patent Covering Anisina(TM) Has Proceeded to Grant Jun 13 2016
Novogen Patent Covering Anisina Has Proceeded to Grant Jun 13 2016
Edison Investment Research Report maintains valuation as Novogen resumes 100% ownership of Cantrixil May 09 2016
Novogen Provides Update On Development Of Cantrixil May 01 2016
Novogen Provides Update on Development of Cantrixil May 01 2016
Cantrixil (TRXE-002-1) Abstract (AACR Annual Meeting 2016) Apr 17 2016
Novogen Receives R&D Tax Incentive Cash Refund Mar 16 2016
Novogen Patent Covering Cantrixil And Trilexium Has Proceeded To Grant Feb 19 2016
Novogen Announces Changes to the Board with New Chairman and Deputy Chairman Appointed Feb 05 2016
Letter to Shareholders from CEO James Garner Jan 31 2016
Novogen appoints new CEO Dec 09 2015
Novogen Appoints Dr James Garner as Chief Executive Officer Dec 09 2015
NOVOGEN LTD Financials Dec 08 2015
Novogen Engages Contract Research Organisation to Conduct Cantrixil Phase 1 Clinical Trial Nov 23 2015
Novogen Patent Covering Cantrixil and Trilexium Accepted in Australia Nov 11 2015
Preclinical Studies Justify Mode of Delivery and Dosing Regimen for Anisina Nov 10 2015
Novogen Applies for Long-Term Options Listing on ASX Sep 30 2015
Novogen Applies for Long-term Options Listing Sep 29 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)